Thursday, October 21, 2004

From Health Canada:
Association of EPREX (epoetin alfa) with thrombotic vascular events -Janssen-Ortho Inc.
Results of recent investigational studies using EPREX and other erythropoietin products have indicated an increased risk of blood clot formation in patients with cancer who were treated to raise their red blood cells to a level higher than the typical target in this population. In some cases, these blood clots were fatal.

No comments: